Search results for "Fibrosis"

showing 10 items of 901 documents

Podoplanin expression in oral potentially malignant disorders and oral squamous cell carcinoma

2017

Background Podoplanin is a type I transmembrane sialomucin-like glycoprotein that is specifically expressed in lymphatic endothelial cells. Studies have shown that assessment of podoplanin expression in the epithelial cells can be used to predict the malignant transformation of potentially malignant disorders and the metastatic tendency of primary head and neck squamous cell carcinoma. The aim of our study was to compare the expression of podoplanin in oral leukoplakia, oral submucous fibrosis and oral squamous cell carcinoma with that in normal buccal mucosa by immunohistochemical methods. Material and methods Immunohistochemical expression of podoplanin was analyzed in 20 cases each of or…

0301 basic medicinePathologymedicine.medical_specialtymedicine.drug_classgovernment.form_of_governmentMonoclonal antibodyMalignant transformation03 medical and health sciences0302 clinical medicineDownregulation and upregulationmedicineGeneral DentistryOral Medicine and Pathologybusiness.industryResearchmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Head and neck squamous-cell carcinomaLymphatic Endotheliumstomatognathic diseases030104 developmental biologyOral submucous fibrosisPodoplanin030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASgovernmentImmunohistochemistrybusiness
researchProduct

A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expressio…

2019

Aberrant activation of the JAK/STAT pathway is thought to be the critical event in the pathogenesis of the chronic myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia and primary myelofibrosis. The most frequent genetic alteration in these pathologies is the activating JAK2V617F mutation, and expression of the mutant gene in mouse models was shown to cause a phenotype resembling the human diseases. Given the body of genetic evidence, it has come as a sobering finding that JAK inhibitor therapy only modestly suppresses the JAK2V617F allele burden, despite showing clear benefits in terms of reducing splenomegaly and constitutional symptoms in patients. To gain a better …

0301 basic medicinePhysiologyClone (cell biology)Mice0302 clinical medicineAnimal CellsBone MarrowImmune PhysiologyMedicine and Health SciencesBlood and Lymphatic System ProceduresTransgenesBone Marrow TransplantationRegulation of gene expressionMultidisciplinaryQRAnimal ModelsBody FluidsPhenotypesBloodExperimental Organism Systems030220 oncology & carcinogenesisMedicineAnatomyCellular TypesResearch ArticleGenetically modified mousePlateletsTransgeneScienceImmunologyMutation MissenseMice TransgenicMouse ModelsSurgical and Invasive Medical ProceduresBone Marrow CellsBiologyResearch and Analysis Methods03 medical and health sciencesModel OrganismsmedicineGeneticsAnimalsHumansAlleleProgenitor cellMyelofibrosisMolecular Biology TechniquesMolecular BiologyTransplantationMyeloproliferative DisordersBlood CellsEssential thrombocythemiaBiology and Life SciencesCell BiologyJanus Kinase 2medicine.diseaseHematopoietic Stem CellsDisease Models Animal030104 developmental biologyAmino Acid SubstitutionGene Expression RegulationImmune SystemCancer researchAnimal StudiesSpleenCloningPLoS ONE
researchProduct

Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease

2017

BACKGROUND AND AIMS: Hepatic cholesterol deposition drives inflammation and fibrosis in non-alcoholic steatohepatitis (NASH). The Niemann-Pick type C2 (NPC2) protein plays an important role in regulating intracellular cholesterol trafficking and homeostasis. We hypothesized that intravenous NPC2 supplementation reduces cholesterol accumulation, hepatic inflammation and fibrogenesis in a nutritional NASH rat model.METHODS: Rats were fed a high-fat, high-cholesterol (HFHC) diet for four weeks resulting in moderately severe NASH. Animals were treated with intravenous NPC2 or placebo twice weekly for either the last two weeks or the entire four weeks. End-points were liver/body- and spleen/body…

0301 basic medicinePhysiologyGene Expressionlcsh:MedicinePathology and Laboratory MedicineBiochemistrychemistry.chemical_compound0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisImmune PhysiologyMedicine and Health Scienceslcsh:ScienceImmune ResponseSterol Regulatory Element Binding ProteinsInnate Immune SystemMultidisciplinarybiologyLiver DiseasesReverse cholesterol transportFatty liverIntracellular Signaling Peptides and ProteinsLipidsCholesterolLiverCytokinesLiver FibrosisFemale030211 gastroenterology & hepatologylipids (amino acids peptides and proteins)Research Articlemedicine.medical_specialtyImmunologyBiological Transport ActiveGastroenterology and HepatologyCollagen Type I03 medical and health sciencesSigns and SymptomsDiagnostic MedicineInternal medicineGeneticsmedicineAnimalsRats WistarGlycoproteinsNutritionInflammationbusiness.industryCholesterollcsh:RBiology and Life Sciencesnutritional and metabolic diseasesMolecular Developmentmedicine.diseaseDietary FatsFibrosisRatsDietCollagen Type I alpha 1 ChainPPAR gammaFatty LiverDisease Models Animal030104 developmental biologyEndocrinologychemistryImmune SystemABCA1LDL receptorbiology.proteinlcsh:QSteatohepatitisCarrier ProteinsbusinessDevelopmental BiologyLipoprotein
researchProduct

The microbiome in respiratory medicine: current challenges and future perspectives

2017

The healthy lung has previously been considered to be a sterile organ because standard microbiological culture techniques consistently yield negative results. However, culture-independent techniques report that large numbers of microorganisms coexist in the lung. There are many unknown aspects in the field, but available reports show that the lower respiratory tract microbiota: 1) is similar in healthy subjects to the oropharyngeal microbiota and dominated by members of the Firmicutes, Bacteroidetes and Proteobacteria phyla; 2) shows changes in smokers and well-defined differences in chronic respiratory diseases, although the temporal and spatial kinetics of these changes are only partially…

0301 basic medicinePulmonary and Respiratory MedicineCystic FibrosisRespiratory SystemDiseaseBiologyCystic fibrosisMicePulmonary Disease Chronic Obstructive03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineRisk FactorsTerminology as TopicProteobacteriaPulmonary MedicinemedicineAnimalsHumansIdiopathic Interstitial PneumoniasMicrobiomeLung11 Medical and Health SciencesBronchiectasisLungBacteroidetesMicrobiotamedicine.diseasebiology.organism_classificationBronchiectasis030104 developmental biologymedicine.anatomical_structure030228 respiratory systemHost-Pathogen InteractionsImmunologyDysbiosisProteobacteriaDysbiosisEuropean Respiratory Journal
researchProduct

Heat shock protein: a hot topic in idiopathic pulmonary fibrosis

2017

HSP90 inhibition could be an exciting new treatment strategy for IPF http://ow.ly/HfKY306uvxw

0301 basic medicinePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyPulmonary Fibrosis03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineHeat shock proteinPulmonary fibrosismedicineHumansHeat-Shock Proteinsbiologybusiness.industrymedicine.diseaseImmunohistochemistryHsp90Idiopathic Pulmonary Fibrosis030104 developmental biology030228 respiratory systemImmunologybiology.proteinImmunohistochemistryTreatment strategybusinessEuropean Respiratory Journal
researchProduct

Heat shock protein-90 toward theranostics: a breath of fresh air in idiopathic pulmonary fibrosis.

2017

Heat shock proteins are potential biomarkers and therapeutic targets in idiopathic pulmonary fibrosis http://ow.ly/fHVP30hJUOl

0301 basic medicinePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyTheranostic NanomedicinePulmonary FibrosisRespiratory SystemHSP90 Heat-Shock ProteinsTheranostic Nanomedicine03 medical and health sciencesIdiopathic pulmonary fibrosisFresh airHeat shock proteinPulmonary fibrosisMedicineHumansHSP90 Heat-Shock ProteinsRespiratory systemMyofibroblastsHeat-Shock Proteinsbusiness.industrymedicine.diseaseIdiopathic Pulmonary Fibrosis030104 developmental biologyPotential biomarkersbusinessThe European respiratory journal
researchProduct

JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study

2018

BackgroundPulmonary hypertension (PH) is a common disorder in patients with idiopathic pulmonary fibrosis (IPF) and portends a poor prognosis. Recent studies using vasodilators approved for PH have failed in improving IPF mainly due to ventilation (V)/perfusion (Q) mismatching and oxygen desaturation. Janus kinase type 2 (JAK2) is a non-receptor tyrosine kinase activated by a broad spectrum of profibrotic and vasoactive mediators, but its role in PH associated to PH is unknown.ObjectiveThe study of JAK2 as potential target to treat PH in IPF.Methods and resultsJAK2 expression was increased in pulmonary arteries (PAs) from IPF (n=10; 1.93-fold; P=0.0011) and IPF+PH (n=9; 2.65-fold; P<0.00…

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyHypertension PulmonaryBlotting WesternMyocytes Smooth MuscleFluorescent Antibody TechniqueVasodilationVascular RemodelingReal-Time Polymerase Chain ReactionVascular remodelling in the embryo03 medical and health sciencesIdiopathic pulmonary fibrosisTransforming Growth Factor betaRight ventricular hypertrophyInternal medicinepulmonary hypertensionAnimalsHumansMedicineRNA Small InterferingRats WistarCells CulturedCell ProliferationBKCaJanus kinase 2biologybusiness.industryEndothelial CellsJanus Kinase 2idiopathic pulmonary fibrosismedicine.diseaseImmunohistochemistryPulmonary hypertensionIdiopathic Pulmonary FibrosisTriterpenesRatsPhenotype030104 developmental biologyJAK2biology.proteinCardiologyAnimal studiesJanus kinasebusinessSignal TransductionPulmonary artery smooth muscle cells Pulmonary artery endothelial cells.Thorax
researchProduct

Addition of the Aldose Reductase Inhibitor Benzofuroxane Derivative BF-5m to Prolonged and Moderate Exercise Training Enhanced Protection of the Rat …

2019

Moderate exercise training may not be sufficient to exert beneficial effects on the cardiovascular system because of the long-term multifactorial etiology of diabetic complications. The addition of a proper pharmacological tool to the physical exercise should improve the outcomes of the diabetic damage. Here it is shown that 8 weeks exercise training of type 1 diabetic Sprague-Dawley (SD) rats resulted in a significantly increased heart rate, a 14% increase in the left ventricular ejection fraction (LVEF) increased plasma insulin levels and a 13% decrease in plasma glucose with respect to sedentary animals. The training also resulted in a 22% reduction in cardiac QT interval from a diabetic…

0301 basic medicineQT intervalmedicine.medical_specialtyPhysical exerciseDiabeteQT interval03 medical and health sciences0302 clinical medicineFibrosisInternal medicineDiabetes mellitusmedicinePharmacology (medical)Original ResearchPharmacologyAldose reductaseType 1 diabetesEjection fractiondiabetesexercisebusiness.industrylcsh:RM1-950medicine.diseaseAldose reductase inhibitor030104 developmental biologyEndocrinologylcsh:Therapeutics. Pharmacology030220 oncology & carcinogenesisbenzofuroxanebusinessaldose-reductasemedicine.drugFrontiers in Pharmacology
researchProduct

Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C.

2017

Background and aims A recent meta-analysis revealed that the genotype PNPLA3 rs738409 GG is associated with a higher risk of hepatic steatosis (HS) in Caucasian patients with chronic hepatitis C (CHC). However, controversial results were found regarding Asian populations. Furthermore, previous studies have shown a negative association between interferon lambda 3 (IFNL3) rs12979860 CC and HS in Caucasian CHC patients, but there have been no reports indicating any such association in Asian populations. In this study, then, we investigated the association of PNPLA3 and IFNL3 polymorphisms with HS in Asian CHC patients. Methods We enrolled consecutive CHC patients who underwent liver biopsy pri…

0301 basic medicineRNA virusesMaleSteatosisHeredityPhysiologylcsh:MedicineHepacivirusChronic liver diseasePathology and Laboratory MedicineGastroenterologyBody Mass IndexCytopathologyLiver disease0302 clinical medicineEndocrinologyGenotypeMedicine and Health Scienceslcsh:ScienceMultidisciplinaryAlcohol Consumptionmedicine.diagnostic_testHepatitis C virusFatty liverHepatitis CMedical microbiologyMiddle AgedGenetic MappingPhysiological ParametersLiverLiver biopsyViruses030211 gastroenterology & hepatologyFemalePathogensResearch ArticleAdultmedicine.medical_specialtyEndocrine DisordersVariant GenotypesMicrobiologyPolymorphism Single Nucleotide03 medical and health sciencesAsian PeopleInternal medicinemedicineGeneticsDiabetes MellitusHumansGenetic Predisposition to DiseaseAllelesGenetic Association StudiesNutritionAgedFlavivirusesbusiness.industryInterleukinsBody Weightlcsh:ROrganismsViral pathogensBiology and Life SciencesMembrane ProteinsLipaseHepatitis C Chronicmedicine.diseaseFibrosisHepatitis virusesDietMicrobial pathogensFatty Liver030104 developmental biologyAnatomical PathologyGenetic LociMetabolic Disorderslcsh:QInterferonsSteatosisbusinessBody mass indexDevelopmental BiologyPLoS ONE
researchProduct

From Genesis to Revelation: The Role of Inflammatory Mediators in Chronic Respiratory Diseases and their Control by Nucleic Acid-based Drugs.

2015

Asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis, are among the most common chronic diseases and their prevalence is increasing. Each of these diseases is characterized by the secretion of cytokines and pro-inflammatory molecules which are thought to play a critical role in their pathogenesis. Moreover, immune cells, particularly neutrophils, macrophages and dendritic cells as well structural cells such as epithelial and airway smooth muscle cells are also involved in the pathogenic cycle of these diseases. There is a pressing need for the development of new therapies for these pulmonary diseases, particularly as no existing treatment has bee…

0301 basic medicineSmall interfering RNARespiratory diseasessiRNA deliveryHMGB1 (high-mobility group box 1)medicine.medical_treatmentGenetic enhancementOligonucleotidesPharmaceutical Science02 engineering and technologyBiologySmall InterferingPathogenesis03 medical and health sciencesIdiopathic pulmonary fibrosisImmune systemRNA interferenceNucleic AcidsmedicineAnimalsHumansAntisenseHMGB1 ProteinRNA Small InterferingCatalyticLungNABDs deliveryDNADNA CatalyticGenetic TherapyOligonucleotides Antisense021001 nanoscience & nanotechnologymedicine.diseaseRespiration Disorders030104 developmental biologyCytokinemedicine.anatomical_structureImmunologyChronic DiseaseRNAInflammation Mediators0210 nano-technologyHMGB1 (high-mobility group box 1); Inflammation mediators; NABDs delivery; Respiratory diseases; siRNA delivery; Animals; Chronic Disease; DNA Catalytic; HMGB1 Protein; Humans; Inflammation Mediators; Nucleic Acids; Oligonucleotides Antisense; RNA Small Interfering; Respiration Disorders; Genetic TherapyCurrent drug delivery
researchProduct